Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 7
Submit an article Journal homepage
399
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment

Mark-Alexander SchwarzbichDepartment of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany;
,
Tilman SchöningDepartment of Pharmacy, University Hospital Heidelberg, Heidelberg, Germany
,
Martin CremerDepartment of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany;
,
Katharina LisenkoDepartment of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany;
,
Anthony D. HoDepartment of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany;
&
Matthias Witzens-HarigDepartment of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany; Correspondence[email protected]
Pages 1723-1726 | Received 25 Mar 2015, Accepted 19 Oct 2015, Published online: 16 Mar 2016

References

  • Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapyplus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
  • Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alonein young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391.
  • Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than thestandard IPI for patients with diffuse large B-cell lymphoma treatedwith R-CHOP. Blood. 2007;109:1857–1861.
  • Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimenswith autologous transplantation for relapsed large B-cell lymphoma inthe rituximab era. J Clin Oncol. 2010;28:4184–4190.
  • Hoelzer D, Hiddemann W, Baumann A, et al. High survival rate in adult Burkitt’s lymphoma/leukemia and diffuse large B-cell lymphoma with mediastinal involvement. Blood (Suppl). 2007;110:518.
  • Mato A, Feldman T, Zielonka T, et al. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54:2606–2612.
  • García-Suárez J, Bañas H, Arribas I, et al. Doseadjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. Br J Haematol. 2007;136:276–285.
  • Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13:1250–1259.
  • Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin andmitoxantrone in the treatment of elderly patients with advanced diffuse non‐Hodgkin’s lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol. 1995;13:2530–2539.
  • Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressive non‐Hodgkin’s lymphoma: disease presentation, response to treatment, and survival – a Grouped’Etude des Lymphomes de l’Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997;15:2945–2953.
  • Tirelli U, Errante D, van Glabbeke M, et al. CHOP is the standard regimen in patients > 70 years of age with intermediate‐grade and high‐grade non‐Hodgkin’s lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol. 1998;16:27–34.
  • Pfreundschuh M, Truemper L, Kloess M, et al. Two‐weekly of 3‐weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL‐B2 trial of the DSHNHL. J Clin Oncol. 2004;104:634–641.
  • Duehrsen U, Hüttman A, Mueller S, et al. Positron emission tomography (PET) guided therapy of aggressive lymphomas – a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL Trial). Blood (Suppl). 2014;124:391.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.